title: Clopidogrel, CYP2C19 and proton pump inhibitors: what we know and what it means.
authors.affiliation: Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA.
authors.forename: Sudharshan
authors.initials: S
authors.lastname: Hariharan
authors.forename: Mary Ross
authors.initials: MR
authors.lastname: Southworth
authors.forename: Rajanikanth
authors.initials: R
authors.lastname: Madabushi
mesh_terms: D000077144:Clopidogrel; D065731:Cytochrome P-450 CYP2C19 / Q000235:genetics / Q000378:metabolism*; D065689:Cytochrome P-450 CYP2C19 Inhibitors / Q000008:administration & dosage*; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics*; D054328:Proton Pump Inhibitors / Q000008:administration & dosage*; D013988:Ticlopidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics
chemical_list: D065689:Cytochrome P-450 CYP2C19 Inhibitors; D010975:Platelet Aggregation Inhibitors; D054328:Proton Pump Inhibitors; D000077144:Clopidogrel; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D013988:Ticlopidine
keywords: cardiovascular (CAR); clinical pharmacology (CPH); drug interactions; pharmacogenomics; pharmacokinetics and drug metabolism